Lido Advisors
VNDA icon

Lido Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Lido Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.9K Buy
10,110
+110
+1% +$719 ﹤0.01% 2076
2026
Q1 		$69.1K Sell
10,000
-100
-1% -$771 ﹤0.01% 1889
2025
Q4 		$50.4K Hold
10,100
– – ﹤0.01% 1884
2025
Q3 		$50.4K Sell
10,100
-2,775
-22% -$12.8K ﹤0.01% 1791
2025
Q2 		$60.8K Hold
12,875
– – ﹤0.01% 1610
2025
Q1 		$59.1K Hold
12,875
– – ﹤0.01% 1471
2024
Q4 		$61.7K Buy
12,875
+1,850
+17% +$8.88K ﹤0.01% 1467
2024
Q3 		$51.7K Buy
11,025
+1,000
+10% +$5.36K ﹤0.01% 1428
2024
Q2 		$56.6K Hold
10,025
– – ﹤0.01% 1373
2024
Q1 		$41.2K Hold
10,025
– – ﹤0.01% 1354
2023
Q4 		$42.3K Buy
10,025
+25
+0.3% +$101 ﹤0.01% 1318
2023
Q3 		$43.2K Buy
+10,000
New +$55.6K ﹤0.01% 1175

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lido Advisors's VNDA Position: Q2 2026 in Review

Lido Advisors increased its Vanda Pharmaceuticals (VNDA) stake by 1.1% in Q2 2026, buying an estimated $719 and bringing the position to 10,110 shares worth $61.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2076.

Lido Advisors first reported a position in VNDA in Q3 2023 and has held it in 12 quarters since. The position peaked at $69.1K in Q1 2026. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Lido Advisors held 10,110 shares of Vanda Pharmaceuticals worth $61.9K as of Q2 2026.
  • Lido Advisors bought 110 Vanda Pharmaceuticals shares in Q2 2026, an estimated $719.
  • Vanda Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #2076 holding.
  • Lido Advisors first reported a position in Vanda Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Lido Advisors's Vanda Pharmaceuticals position peaked at $69.1K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.